CN106619702A - 一种治疗肺结核的药物 - Google Patents
一种治疗肺结核的药物 Download PDFInfo
- Publication number
- CN106619702A CN106619702A CN201611118326.XA CN201611118326A CN106619702A CN 106619702 A CN106619702 A CN 106619702A CN 201611118326 A CN201611118326 A CN 201611118326A CN 106619702 A CN106619702 A CN 106619702A
- Authority
- CN
- China
- Prior art keywords
- parts
- treatment
- phthisical medicine
- narcotine
- piperacillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 229940079593 drug Drugs 0.000 title abstract description 7
- 201000008827 tuberculosis Diseases 0.000 title abstract description 5
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims abstract description 19
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims abstract description 19
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 19
- 229930101531 artemisinin Natural products 0.000 claims abstract description 19
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims abstract description 19
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims abstract description 19
- 229960002292 piperacillin Drugs 0.000 claims abstract description 19
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims abstract description 19
- 229910052939 potassium sulfate Inorganic materials 0.000 claims abstract description 19
- 235000011151 potassium sulphates Nutrition 0.000 claims abstract description 19
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 18
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 18
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 18
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract description 18
- 229960001225 rifampicin Drugs 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 12
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 36
- 229940050957 opium tincture Drugs 0.000 claims description 18
- 229930183339 qinghaosu Natural products 0.000 claims description 18
- 229960005137 succinic acid Drugs 0.000 claims description 18
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 17
- 229960003855 solifenacin Drugs 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- -1 nikethamidum Chemical compound 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 abstract 1
- 235000005241 Cistus ladanifer Nutrition 0.000 abstract 1
- 240000008772 Cistus ladanifer Species 0.000 abstract 1
- 229960004191 artemisinin Drugs 0.000 abstract 1
- 229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003226 nikethamide Drugs 0.000 abstract 1
- 229960001368 solifenacin succinate Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 230000007170 pathology Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 241000209094 Oryza Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010051093 Cardiopulmonary failure Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- OPCRGEVPIBLWAY-QNRZBPGKSA-N ethyl (2E,4Z)-deca-2,4-dienoate Chemical compound CCCCC\C=C/C=C/C(=O)OCC OPCRGEVPIBLWAY-QNRZBPGKSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗肺结核的药物，所述治疗肺结核的药物，按照重量份的主要原料为：利福平23‑27份、阿拉伯糖10‑20份、青蒿素6‑9份、尼可刹米7‑13份、琥珀酸索利那新10‑20份、哌拉西林1‑2份、硝酸异山梨酯8‑10份、阿片酊5‑6份、那可汀1.1‑1.5份、硫酸钾0.3‑0.6份。本发明药物对肺结核均能高效、时间短、平稳的治愈，为患者提供了一种使用方便、疗效好的抗肺结核药物。
Description
技术领域
本发明涉及一种医药制备领域，具体是一种治疗肺结核的药物。
背景技术
肺结核是由结核分枝杆菌引发的肺部感染性疾病，通过呼吸道传播。健康人感染结核菌并不一定发病，只有在机体免疫力下降时才发病。肺结核是一种慢性传染，根据致病病毒的强弱、人体抵抗力的不同，在症状上表现也就不相同，早期：感觉乏力，早上起床比较累，下午表现无力，晚上反而无法控制兴奋而导致失眠，而且在无其它原因的情况下消瘦，长时间的咳嗽和咳痰，慢慢加剧痰中带血，呼吸困难，在入睡和睡醒时出现全身盗汗，而且出现全身疲劳和虚弱。并且出现体温波动，中午或劳累后出现体温升高，甚至低热，并伴有胸闷、胸痛的现象。妇女在无妇科疾病或者怀孕的情况出现月经不调或停经。当发展到骨蒸潮热与手足心热，面颧发红，口干喜冷饮，舌红脉细数，甚至面色不华，神疲体软，咳语声微，纳呆便溏、痰多清稀、畏风自汗、舌淡苔白有齿痕，大量咯血并伴有心肺功能衰竭。
因此，急需研发一种适合疗效好、速度快、价格低、无毒副作用的西药组合物。
发明内容
本发明的目的在于提供一种治疗肺结核的药物，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
一种治疗肺结核的药物，按照重量份的主要原料为：利福平23-27份、阿拉伯糖10-20份、青蒿素6-9份、尼可刹米7-13份、琥珀酸索利那新10-20份、哌拉西林1-2份、硝酸异山梨酯8-10份、阿片酊5-6份、那可汀1.1-1.5份、硫酸钾0.3-0.6份。
作为本发明进一步的方案：所述治疗肺结核的药物，按照重量份的主要原料为：利福平25-27份、阿拉伯糖12-16份、青蒿素7-8份、尼可刹米9-12份、琥珀酸索利那新13-17份、哌拉西林1-2份、硝酸异山梨酯8-10份、阿片酊5-6份、那可汀1.2-1.4份、硫酸钾0.3-0.6份。
作为本发明进一步的方案：所述治疗肺结核的药物，按照重量份的主要原料为：利福平26份、阿拉伯糖14份、青蒿素8份、尼可刹米11份、琥珀酸索利那新15份、哌拉西林2份、硝酸异山梨酯9份、阿片酊6份、那可汀1.3份、硫酸钾0.5份。
一种治疗肺结核的药物的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4-8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
作为本发明进一步的方案：具体步骤中混合6min。
与现有技术相比，本发明的有益效果是：
本发明药物对肺结核均能高效、时间短、平稳的治愈，为患者提供了一种使用方便、疗效好的抗肺结核药物。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种治疗肺结核的药物，按照重量份的主要原料为：利福平23份、阿拉伯糖10份、青蒿素6份、尼可刹米7份、琥珀酸索利那新10份、哌拉西林1份、硝酸异山梨酯8份、阿片酊5份、那可汀1.1份、硫酸钾0.3份。
一种治疗肺结核的药物的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
实施例2
一种治疗肺结核的药物，按照重量份的主要原料为：利福平25份、阿拉伯糖12份、青蒿素7份、尼可刹米9份、琥珀酸索利那新13份、哌拉西林1份、硝酸异山梨酯8份、阿片酊5份、那可汀1.2份、硫酸钾0.3份。
一种治疗肺结核的药物的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合5min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
实施例3
一种治疗肺结核的药物，按照重量份的主要原料为：利福平26份、阿拉伯糖14份、青蒿素8份、尼可刹米11份、琥珀酸索利那新15份、哌拉西林2份、硝酸异山梨酯9份、阿片酊6份、那可汀1.3份、硫酸钾0.5份。
一种治疗肺结核的药物的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合6min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
实施例4
一种治疗肺结核的药物，按照重量份的主要原料为：利福平27份、阿拉伯糖16份、青蒿素8份、尼可刹米12份、琥珀酸索利那新17份、哌拉西林2份、硝酸异山梨酯10份、阿片酊6份、那可汀1.4份、硫酸钾0.6份。
一种治疗肺结核的药物的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
实施例5
一种治疗肺结核的药物，按照重量份的主要原料为：利福平27份、阿拉伯糖20份、青蒿素9份、尼可刹米13份、琥珀酸索利那新20份、哌拉西林2份、硝酸异山梨酯10份、阿片酊6份、那可汀1.5份、硫酸钾0.6份。
一种治疗肺结核的药物的制备方法，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
对比例1
利福平胶囊，广东华南药业集团有限公司，0.15g一粒，一天三次，一次一粒。
对比例2
异烟肼片，上海医药(集团)有限公司信谊制药总厂，0.1g一片，一天三次，一次一片。
对比例3
吡嗪酰胺片，广东台城制药股份有限公司，0.25g一片，一天三次，一次一片。
临床试验
1.1临床资料
选取2015年6月至2015年12月山东济南某医疗机构收治的200例肺结核感染患者，分为一个处理组和三个对照组，每组50例，其中所有患者均符合中华医学会结核病分会制定的肺结核诊断标准，经影像学和实验室检查在肺部均发现活动性病变。
处理组中，男性25例，女性25例，年龄20-75岁，平均年龄(39±2.6)岁，病程1-5年，平均病程(3.6±1.2)年；14例为原发性肺结核，36例继发性肺结核；症状：15例患者表现为咳血症状，9例表现为乏力、消瘦，10例表现为发热和盗汗，8例表现为胸痛和气短，8例患者合并结合性胸膜炎；病位：20例患者病变限于1个肺野，19例患者病变限于二到三个肺野，11例患者病变限于四到五个肺野。
对照组中，男性70例，女性80例，年龄19-73岁，平均年龄(40±2.5)岁，病程1-5年，平均病程(3.5±1.0)年；46例为原发性肺结核，104例继发性肺结核；症状：其中52例患者表现为咳血症状，25例表现为乏力、消瘦，33例表现为发热和盗汗，20例表现为胸痛和气短，20例患者合并结合性胸膜炎；病位：52例患者病变限于1个肺野，61例患者病变限于二到三个肺野，34例患者病变限于四到五个肺野；随后将对照组均等地平分成三个小组，达到三个小组之间的差异无统计学意义。
两组(处理组和对照组)患者的基本资料、临床症状和病位范围比较，其差异无统计学意义(p>0.05)，有可比性。
1.2治疗方法
对照组中的三个小组，分别按照对比例1-3公开的药物及使用说明进行服用。
处理组选用本发明实施例3制备的药物，每次0.1g，每天三次。
按以上方案，对照组持续治疗1个月为1疗程，处理组持续治疗1个月为1疗程，治疗期间每月要定期检查患者的肝功能。3个疗程后，观察两组患者的临床疗效和复发率。
1.3疗效判定
治愈：患者的咳嗽、发热、呕血症状消失，经影响学检查病灶完全消失或已经纤维化、钙化等，痰抗酸菌检呈连续转阴性，对于残留空洞，停药后痰菌需连续转阴一年以上、胸膜炎患者胸水完全吸收；显效：患者的咳嗽、发热、呕血症状消失，经影像学检查病灶吸收明显、空洞闭合或缩小在3个月以上，痰抗酸菌检呈阴性；有效：患者的咳嗽、发热、呕血症状消失，经影像学检查病灶吸收明显或没有变化，痰抗酸菌检连续转阴性；无效：患者的症状没有任何改善或加重视；恶化：患者的痰菌阳转，病变增多、空洞增大或出现新空洞；复发：3个疗程结束后，一年复查时如果已经转阴的痰菌再次阳转或有新病灶出现视为。
总有效率＝(痊愈+显效+有效)/总例数*100％。
1.4统计学分析采用spss13.0统计学软件对数据进行统计分析，采用x2检验计数资料，以P<0.05为统计学意义标准。
2结果
3个疗程结束后，处理组有38例治愈，7例显效，4例有效，1例无效，0例恶化，0例复发，总有效率98.0％；而对照组有7例治愈，10例显效，14例有效，11例无效，5例恶化，3例复发，总有效率62.0％。
一年后复查，处理组有48例治愈，2例显效，0例有效，0例无效，0例恶化，0例复发，总有效率100.0％；而对照组有2例治愈，4例显效，5例有效，26例无效，1例恶化，12例复发，总有效率22.0％。
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。
Claims (5)
1.一种治疗肺结核的药物，其特征在于，按照重量份的主要原料为：利福平23-27份、阿拉伯糖10-20份、青蒿素6-9份、尼可刹米7-13份、琥珀酸索利那新10-20份、哌拉西林1-2份、硝酸异山梨酯8-10份、阿片酊5-6份、那可汀1.1-1.5份、硫酸钾0.3-0.6份。
2.根据权利要求1所述的治疗肺结核的药物，其特征在于，所述治疗肺结核的药物，按照重量份的主要原料为：利福平25-27份、阿拉伯糖12-16份、青蒿素7-8份、尼可刹米9-12份、琥珀酸索利那新13-17份、哌拉西林1-2份、硝酸异山梨酯8-10份、阿片酊5-6份、那可汀1.2-1.4份、硫酸钾0.3-0.6份。
3.根据权利要求1所述的治疗肺结核的药物，其特征在于，所述治疗肺结核的药物，按照重量份的主要原料为：利福平26份、阿拉伯糖14份、青蒿素8份、尼可刹米11份、琥珀酸索利那新15份、哌拉西林2份、硝酸异山梨酯9份、阿片酊6份、那可汀1.3份、硫酸钾0.5份。
4.一种如权利要求1-3任一所述的治疗肺结核的药物的制备方法，其特征在于，具体步骤为：
首先，在医药级洁净区内，按上述计量比称取对利福平、阿拉伯糖、青蒿素、尼可刹米、琥珀酸索利那新、哌拉西林、硝酸异山梨酯、阿片酊、那可汀、硫酸钾，过筛，机械混匀后添加超纯水，放置制药混合机中，混合4-8min，控制RSD≤5％，混合后压片并低温干燥，温度控制在15℃，包装即得治疗肺结核的药物。
5.根据权利要求4所述的治疗肺结核的药物的制备方法，其特征在于，具体步骤中混合6min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611118326.XA CN106619702A (zh) | 2016-12-07 | 2016-12-07 | 一种治疗肺结核的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611118326.XA CN106619702A (zh) | 2016-12-07 | 2016-12-07 | 一种治疗肺结核的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619702A true CN106619702A (zh) | 2017-05-10 |
Family
ID=58819990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611118326.XA Pending CN106619702A (zh) | 2016-12-07 | 2016-12-07 | 一种治疗肺结核的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619702A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1388758A (zh) * | 2000-08-09 | 2003-01-01 | 灵药生物技术有限公司 | 抗结核病药物的新颖的药学组合物及其制备方法 |
-
2016
- 2016-12-07 CN CN201611118326.XA patent/CN106619702A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1388758A (zh) * | 2000-08-09 | 2003-01-01 | 灵药生物技术有限公司 | 抗结核病药物的新颖的药学组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1325083C (zh) | 一种用于除湿止痒的药物组合物及其制备方法和用途 | |
| CN101116503A (zh) | 降血糖的保健品及其制备方法 | |
| CN103405697A (zh) | 一种治疗肺结核的药物 | |
| CN101785839A (zh) | 一种治疗咳血的中药组合物及其制备方法 | |
| CN1301743C (zh) | 治疗慢性支气管炎的中药 | |
| CN107669991A (zh) | 一种降低血尿酸水平的药物组合物及其制备方法 | |
| CN106727547A (zh) | 一种治疗肺结核的西药组合及其制备方法 | |
| CN106619702A (zh) | 一种治疗肺结核的药物 | |
| CN106581048A (zh) | 一种治疗肺结核的西药组合及其制备方法 | |
| CN104042811B (zh) | 一种用于治疗支气管哮喘缓解期的外贴复方药物及其制备方法和应用 | |
| CN101732500A (zh) | 一种预防和治疗急慢性咽炎、咽喉炎的药物 | |
| CN106581179A (zh) | 一种治疗浸润型肺结核的药物 | |
| CN103251891A (zh) | 一种治疗气滞血瘀型不稳定性心绞痛的中药外用膏剂 | |
| CN110170035B (zh) | 治疗寻常型银屑病的药物组合物、药物制剂和应用 | |
| CN102441047A (zh) | 治疗缺铁性贫血的中药制剂 | |
| CN104491297B (zh) | 一种治疗复发性尿路感染的中药组合物 | |
| CN1935157B (zh) | 一种用于治疗皮肤病的麦饭石乳膏及其制备方法 | |
| CN101099840A (zh) | 治疗肺结核药物组合物 | |
| CN104491298B (zh) | 一种治疗复发性尿路感染的中药组合物及其制备方法 | |
| Wu et al. | Efficacy of botanical lozenges in the treatment of chronic pharyngitis: a randomized controlled trial | |
| CN110302296B (zh) | 一种治疗肝胃不和，或/和咽部不适的中药组合物及其制备方法和用途 | |
| CN102784344B (zh) | 一种治疗肺结核的中药制剂 | |
| CN106668044A (zh) | 一种治疗慢性支气管炎的西药组合物 | |
| CN104306811B (zh) | 一种治疗儿童寻常型银屑病的中药组合物 | |
| Wang et al. | Effects of Aloe Gel on Lactating Women with Nipple Trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |